Patents Assigned to BioTie Therapies Ltd.
  • Integrin binding peptide and use thereof
    Patent number: 6096707
    Abstract: Cyclic peptides comprising three colinear amino acids, arginine-lysine-lysine (RKK) are provided that bind to the integrin .alpha.2I domain and are potent inhibitors of its interaction with collagens I and IV and laminin-1. Methods of using such peptides to block integrin function and to inhibit cell migration are also provided.
    Type: Grant
    Filed: July 11, 1997
    Date of Patent: August 1, 2000
    Assignee: BioTie Therapies Ltd.
    Inventors: Jyrki Heino, Johanna Ivaska, Jarmo Kapyla
  • Syndecan enhancer element and syndecan stimulation of cellular differentiation
    Patent number: 6017727
    Abstract: A DNA enhancer element and the use of this syndecan enhancer element to regulate the expression of genes are provided.
    Type: Grant
    Filed: December 2, 1996
    Date of Patent: January 25, 2000
    Assignee: BioTie Therapies Ltd.
    Inventors: Markku Jalkanen, Panu Jaakkola, Tapani Vihinen
  • Suppression of tumor cell growth by syndecan-1 ectodomain
    Patent number: 5851993
    Abstract: Methods of reducing tumor growth, including the suppression of tumor growth in a patient, are provided by the administration of efficacious levels of syndecan ectodomain to the extracellular environment of the tumor cell. Pharmaceutically acceptable compositions of syndecan are also provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 22, 1998
    Assignee: BioTie Therapies Ltd.
    Inventors: Markku Jalkanen, Marku Mali